Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q13394
UPID:
MB211_HUMAN
Alternative names:
Protein mab-21-like 1
Alternative UPACC:
Q13394; Q6I9T5
Background:
Putative nucleotidyltransferase MAB21L1, also known as Protein mab-21-like 1, plays a crucial role in embryonic development, particularly in the normal development of the eye. Its ability to bind single-stranded RNA underscores its significance in cellular processes, although its nucleotidyltransferase activity in vivo remains to be fully elucidated.
Therapeutic significance:
MAB21L1 is implicated in Cerebellar, ocular, craniofacial, and genital syndrome, a condition marked by developmental delays, cerebellar hypoplasia, and various physical anomalies. Understanding the role of MAB21L1 could open doors to potential therapeutic strategies for this syndrome.